Latest News

Webcasts The Future of Connected Health and the Top Ten Takeaways from HIMSS

The Future of Connected Health and the Top Ten Takeaways from HIMSS

Join Phunware to explore how connected health will create new opportunities for engaging with patients before, during and after hospital visits.

Pharmaceutical Tecfidera sales slow, Biogen to maintain "significant" sales force

Tecfidera sales slow, Biogen to maintain "significant" sales force

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Pharmaceutical Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Pharmaceutical Merck HCV med's efficacy matches competitors'

Merck HCV med's efficacy matches competitors'

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.

Pharmaceutical Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Pharmaceutical

Mylan's generic Sovaldi launches in India

The hepatitis-C drug is being sold under the name MyHep.

Pharmaceutical Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Pharmaceutical Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

Established products fueled at 12% jump in first-quarter sales.

Pharmaceutical

Actavis case may not serve as Namenda precedent

A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.

Legal/Regulatory

FDA grants Pfizer lung-cancer drug Breakthrough Designation

Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.